Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Najoua Lalaoui

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Seminars in Cell & Developmental Biology|September 17, 2020
25 years of research put RIPK1 in the clinicLin Liu, Najoua Lalaoui
Immunology and Cell Biology|December 7, 2016
Relevance of necroptosis in cancerNajoua Lalaoui, Gabriela Brumatti
Molecular Cell|February 19, 2017
Jekyll & Hyde: The Other Life of the Death Ligand TRAILNajoua Lalaoui, John Silke
F1000Research|January 12, 2019
Recent advances in understanding inhibitor of apoptosis proteinsNajoua Lalaoui, David Lawrence Vaux
Nature Reviews. Rheumatology|December 11, 2025
Monogenic disorders of the TNF signalling pathwayNajoua Lalaoui, Seth L Masters
Trends in Molecular Medicine|February 16, 2017
'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid LeukemiaGabriela Brumatti, Najoua Lalaoui, Andrew H Wei, et al.
Expert Opinion on Therapeutic Targets|October 3, 2007
TRAIL in cancer therapy: present and future challengesDelphine Mérino, Najoua Lalaoui, Alexandre Morizot, et al.
Seminars in Cell & Developmental Biology|March 5, 2015
The molecular relationships between apoptosis, autophagy and necroptosisNajoua Lalaoui, Lisa M Lindqvist, Jarrod J Sandow, et al.
Molecular and Cellular Biology|September 19, 2006
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, et al.
The Journal of Investigative Dermatology|June 26, 2017
Inhibitor of Apoptosis Proteins (IAPs) Limit RIPK1-Mediated Skin InflammationHolly Anderton, James A Rickard, George A Varigos, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Seminars in Cell & Developmental Biology|September 17, 2020
25 years of research put RIPK1 in the clinicLin Liu, Najoua Lalaoui
Immunology and Cell Biology|December 7, 2016
Relevance of necroptosis in cancerNajoua Lalaoui, Gabriela Brumatti
Molecular Cell|February 19, 2017
Jekyll & Hyde: The Other Life of the Death Ligand TRAILNajoua Lalaoui, John Silke
F1000Research|January 12, 2019
Recent advances in understanding inhibitor of apoptosis proteinsNajoua Lalaoui, David Lawrence Vaux
Nature Reviews. Rheumatology|December 11, 2025
Monogenic disorders of the TNF signalling pathwayNajoua Lalaoui, Seth L Masters
Trends in Molecular Medicine|February 16, 2017
'Did He Who Made the Lamb Make Thee?' New Developments in Treating the 'Fearful Symmetry' of Acute Myeloid LeukemiaGabriela Brumatti, Najoua Lalaoui, Andrew H Wei, et al.
Expert Opinion on Therapeutic Targets|October 3, 2007
TRAIL in cancer therapy: present and future challengesDelphine Mérino, Najoua Lalaoui, Alexandre Morizot, et al.
Seminars in Cell & Developmental Biology|March 5, 2015
The molecular relationships between apoptosis, autophagy and necroptosisNajoua Lalaoui, Lisa M Lindqvist, Jarrod J Sandow, et al.
Molecular and Cellular Biology|September 19, 2006
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, et al.
The Journal of Investigative Dermatology|June 26, 2017
Inhibitor of Apoptosis Proteins (IAPs) Limit RIPK1-Mediated Skin InflammationHolly Anderton, James A Rickard, George A Varigos, et al.
Pageof 5